San Diego, CA., October 10, 2012 – Vascular BioSciences announces CEO David Mann will present “CAR Peptide, a Disease Selective Therapeutic Adjuvant For Targeted Drug Therapy” during the 7th Annual Therapeutic Peptide Symposium to be hosted at The Salk Institute in La Jolla, CA on October 25th and 26th, 2012.
“A major limitation in the treatment of disease is the lack of therapeutic selectivity. Our therapeutic peptide adjuvant addresses this need by homing to areas of disease, internalizing into targeted tissues, and enabling co‒administered drugs to achieve selective therapeutic effects,” commented CEO David Mann.
CARSKNKDC (CAR), a 9 amino acid cyclic peptide selectively targets and internalizes into a range of diseased tissues. CAR targets hypertensive vessels, angiogenesis, fibrotic lesions, areas of inflammation, acute lung injury, asthma, wounds, and tumors. Interestingly, CAR peptide also enables a multiplicity of co‒administered drugs to preferentially affect disease tissues to increase localized concentrations of therapeutics without requiring the drug to be conjugated to the CAR peptide adjuvant. There is also evidence to indicate that CAR possesses oral bioavailability. In addition to oral availability, CAR peptide has a long half‒life (27 hours), and no toxic effects seen to date in pre‒clinical models.
About Vascular BioSciences
Vascular BioSciences, a diversified biomedical company with operations in California and North Carolina, provides disease solutions in order to enhance and prolong human life
Vascular BioSciences makes interventional catheters to obtain endoarterial biopsies, provides molecular diagnostic services, and through its majority owned subsidiary VBS Pharmaceuticals, develops targeted therapeutics for patients with difficult‒to‒treat diseases.
About The Peptide Therapeutics Symposium
The Peptide Therapeutics Symposium is a non-profit annual meeting established in 2005 to promote research and development of peptide therapeutics. More information on this year’s symposium as well as previous symposiums can be found at: www.peptidetherapeutics.org.
For more information, please contact email@example.com